Mild Water-filtered Infrared-A Whole-body Hyperthermia in Patients With Post-COVID Syndrome (HyPoCo)

Launched by UNIVERSITÄT DUISBURG-ESSEN · Jan 11, 2024

Keywords

ClinConnect Summary

This clinical trial, called HyPoCo, is exploring a treatment called mild water-filtered whole-body hyperthermia for patients suffering from post-COVID syndrome. Post-COVID syndrome can cause ongoing symptoms like fatigue and decreased quality of life after recovering from COVID-19. The study aims to see if this gentle heating therapy can help improve these symptoms. The trial will last about two weeks, with participants receiving treatment twice a week, and there will be a follow-up period of three months to check on their progress.

To be eligible for the trial, participants must be between 18 and 75 years old and have a confirmed diagnosis of post-COVID syndrome, specifically experiencing significant fatigue. However, certain individuals may not qualify, such as those with severe heart conditions, active cancers, or other serious health issues. If someone is interested in participating, they can expect to receive outpatient treatments in a supportive environment and will have their health monitored throughout the study. This trial is currently recruiting participants, and it represents a hopeful avenue for improving the lives of those affected by lingering COVID-19 symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged between 18 and 75 years
• • Confirmed diagnosis of post-COVID syndrome
• • Fatigue: at least 51.5 points on the MFI-20 scale.
• • Signed declaration of consent
• Exclusion Criteria:
• • Participation in other clinical studies
• • Contraindications for hyperthermia (severe cardiovascular diseases with/above NYHA II, active tumor diseases, acute infections, hyperthyroidism (not adjusted), pregnant and breastfeeding women, epilepsy, high-grade cardiac arrhythmia including atrial fibrillation, multiple sclerosis, major skin lesions, photosensitivity disease, acute exacerbated bronchial asthma/COPD \[Gold II to IV\])
• • Pleuritic chest pain
• • Hyperthyroidism
• • Poorly controlled diabetes mellitus
• • Condition after critical illness due to COVID-19
• • Patients with active tumor disease, with pneumological, rheumatic, endocrine or neurological concomitant diseases (including dementia, epilepsy, multiple sclerosis), in particular neurological diseases associated with cognitive or sensory disorders
• • Severe liver or kidney diseases (liver cirrhosis, post liver transplant, autoimmune hepatitis, dialysis patients, post kidney transplant, acute kidney failure, autoimmune nephropathy)
• • Patients with chronic cannabis use (exception: CBD for myalgia), long-term use of WHO class III opioids (e.g. for myalgia/joint pain), long-term use of immunosuppressive medication (steroids, biologics, MTX, leflunomide, azathioprine)
• • Patients with psychiatric disorders (bipolar disorder, psychosis, schizophrenia, personality disorder)